SEC Form 4 · accession 0001140361-17-014883
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Murray
Officer — President & CEO
Period of report
Mar 24, 2017
Accepted (ET)
Apr 5, 2017 · 3:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.15 | Mar 24, 2017 | A | 450,000 | A | — | Mar 24, 2027 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1The options vest as follows: 1/3 on March 23, 2018; 1/3 on March 23, 2019; 1/3 on March 23, 2020.